Mike Doustdar

like to continue expanding the market, and we will make sure that the price levels are in a way that will make us do that.

Absolutely.

We have made it very clear that we would like to sustain our leadership in diabetes and obesity and go very deep.

We have a fantastic pipeline in both of those therapy areas, but the world is very large.

We are dealing with some close to 2 billion people that are suffering from diabetes, obesity and overweight.

And when you're having an ambition to actually capture as many patients as possible from this very large pool, then you will continue looking not just in your own research shop, but everywhere else to see how complementary-wise you could actually have the best pipeline available and the best offering amongst all your competitors.

It is one of the big stories of the morning.

What is happening with Novo is fascinating, as you say.

Company coming out this morning, cutting revenue, missing on a number of metrics.

But look at the share price.

Last time I checked and it was just up on the screen just a moment ago, up by what?

One, one and a bit percent.

Does that signal maybe that the market believes that this Corsa, this Q3 is the bottom?

Let's ask Mike Dustar.

He is the CEO of this business now.

Great to see you, Mike.

Thanks for spending some time with us this morning.

Is that the right interpretation?

Is this the kind of the bottom?

Is the glass half full from here after being half empty for so long?